EGEmil G. Gasymov

Emil G. Gasymov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emil G. Gasymov has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Unique Clinical Case of Heterotopic Ossification Volume Reduction in a Child with Fibrodysplasia Ossificans Progressiva Based on Whole-Body Multislice Computed Tomography

    by E. G. Gasymov, I. P. Nikishina, V. G. Matkava, А. V. Smirnov, S. V. Arsenyeva, L. M. Blank

    Fibrodysplasia ossificans progressiva (FOP) is an extremely rare genetic disorder inherited in an autosomal dominant manner. The FOP development is caused by a mutation in the ACVR1 gene, which encodes a receptor for bone morphogenetic protein, leading to uncontrolled formation of heterotopic ossifications (HO) and causing complete immobility of the patient. Low-dose multislice computed tomography (LDCT) is considered a “gold standard” for assessing the localization and extent of HO lesions. In addition to its high spatial resolution, LDCT combined with specialized software enables quantitative volumetric measurement of HO areas, which can be extremely valuable for monitoring disease progression. We present a clinical case of FOP in a 2-year-old child, for whom whole-body LDCT was performed for the first time in the Russian Federation, followed by calculation of the total HO volume visualized during examination using integrated software tools.

  • Open Access

    Use of palovarotene in pathogenetic therapy of fibrodysplasia ossificans progressiva: real-world clinical practice experience

    by I. P. Nikishina, V. G. Matkava, S. V. Arsenyeva, E. G. Gasymov

    Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare monogenic disease manifested by an uncontrolled process of generalized heterotopic ossification. The first and only drug that has demonstrated in clinical trials the ability to slow the growth of new ossifications is palovarotene (PVT), a selective agonist of the gamma subtype of the retinoic acid receptor (RARã), which has been approved for the treatment of FOP in certain age groups in several countries. Published real-world data on its use are limited. Objective: to analyze the experience of using PVT in FOP in real-world Russian clinical practice, with an emphasis on detailed patients’ characteristics description and assessment of treatment efficacy and safety. Material and methods. Nineteen patients with severe FOP (mean age 12.4 years; 14 patients younger than 14 years) who met the selection criteria were chosen for PVT therapy. Progression of the total volume of heterotopic ossifications (HO) was assessed using low-dose whole-body computed tomography (LDCT). The number of flare-ups before and during therapy was analyzed. Functional status was assessed using the CAJIS and CHAQ scales. Adverse events (AEs) occurring during treatment were recorded. Results and discussion. All 19 patients with FOP had the classic disease phenotype with a pathogenic variant of the ACVR1 gene. Of these, 15 are currently receiving PVT in the ongoing regimen in combination with the Janus kinase inhibitor tofacitinib (TOFA); in 8 of these patients, treatment duration exceeds 1 year (median 18 months). Another 4 patients are awaiting access to the drug. According to serial LDCT examinations with a 12-month interval, no substantial increase in the total HO volume was detected. No deterioration in functional status was observed during therapy. No serious AEs were recorded. In 14 of 15 patients, mucocutaneous AEs (dryness, pruritus, retinoid dermatitis) of varying severity were observed. Conclusion. Preliminary analysis of PVT use in patients with FOP showed no significant progression of HO and, at the same time, a favorable safety profile. Complementarity of the pathogenetic effects of PVT and TOFA may become a new therapeutic strategy for FOP.

  • Open Access

    The First Russian Experience of Using Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Two Case Reports

    by Irina P. Nikishina, Valeriya G. Matkava, Svetlana V. Arsenyeva, Emil G. Gasymov, Alia N. Arefieva

    Background. Fibrodysplasia ossificans progressiva (FOP) — is an extremely rare genetic disorder with an autosomal dominant type of inheritance. FOP is associated with a genetically determined disorder caused by the presence of a specific mutation in the ACVR1/ALK2 gene encoding the bone morphogenetic protein receptor. FOP is clinically manifested by the unrestrained formation of heterotopic ossifications, leading to a gradual progression of disability up to complete immobility of the patient. At an early age, the disease can be recognized by the presence of characteristic phenotypic stigmas, mainly the characteristic malformation of the thumbs, confirming the diagnosis by molecular genetic analysis. Early diagnosis of FOP avoids unnecessary iatrogenic manipulations and slows down the progression of the disease. Up until recently, there was no therapy that had a pathogenetic effect, preventing the development of ossifications. The first and only drug that has proven its effectiveness as a result of clinical trials and is registered for use in patients with FOP in a number of countries is palovarotene.Case reports: The publication presents the first Russian experience of using palovarotene with a description of two clinical observations of patients with a genetically confirmed diagnosis of FOP. The clinical picture, the difficult path to diagnosis, and the encouraging experience of treating patients, including anti-inflammatory therapy using Janus kinase inhibitors (tofacitinib) and pathogenetic therapy with palovarotene, are described.Conclusion. The aggressive nature of the course of FOP, which inevitably leads to severe disability of patients, necessitates the widespread attention of practitioners to the early diagnosis of FOP, an in-depth study of the factors determining progression, and new opportunities for pathogenetic therapy allow us to count on improving the prognosis of this extremely serious disease.


  • CLINICAL CASE OF CHRONIC MULTIFOCAL NONBACTERIAL OSTEOMYELITIS IN A PATIENT WITH INITIALLY DIAGNOSED SYSTEMIC JUVENILE ARTHRITIS

    by S.O. Salugina, I.P. Nikishina, O.V. Borodacheva, A.N. Arefyeva, E.G. Gasymov

    Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.

  • Open Access

    Рост числа случаев остеонекрозов в «Эпоху Covid-19»: случайность или закономерность?

    by Ч.т. Баймухамедов, А.к. Ботабекова, Э.г. Гасымов, Ж.ш. Лесова, Б.ш. Абшенов, Н.н. Курманали, А.к. Дуйсенова

    Четвертый год пандемии коронавирусной инфекции Covid-19, вызванной SARS Cov-2 (Severe acute respiratory syndrome coronavirus-2, coronavirus infectious disease), унес более 6 800 000 жизней. Практические врачи (прежде всего ревматологи, травматологи, врачи общей практики) все чаще сталкиваются с новой проблемой – остеонекрозом (асептическим некрозом) головки бедренной кости, тяжелым инвалидизирующим заболеванием. Пандемия Covid-19 привела к повышению частоты развития асептических некрозов. Возможно, мы стоим на пороге эпидемии остеонекрозов, учитывая огромное количество переболевших Covid-19 людей и получавших глюкокортикоиды при терапии SARS-Cov-2. По данным статистики «Медицинского центра болезней суставов г. Шымкент» за последние 3 года наблюдается почти трехкратный рост данной патологии. Цель статьи – проанализировать данные литературы и собственные случаи, а также обсудить возможную связь между остеонекрозом и Covid-19, в том числе с лечением коронавирусной инфекции Covid-19 глюкокортикоидами. 6 800 000 астам өмірді қиған SARS-Cov-2 (Severe acute respiratory syndrome coronavirus-2, Covid-19) індет пандемиясының төртінші жылы аяқталуда. Тәжірибелік дәрігерлер (ең алдымен ревматологтар, травматологтар, жалпы тажірибелік дәрігерлер) ауыр мүгедектікке алып келуші патология – жамбас сүйегі ұршығының остеонекрозы (асептикалық некроз) деген жаңа мәселені жиі кездестіруде. Covid-19 пандемиясы асептикалық некроздардың даму жиілігіне алып келеді. «Шымкент қаласының буын аурулары медициналық орталығында» соңғы 3 жылда осы патологияның үш есе өсуі байқалуда. Мүмкін, пандемия SARS-Cov-2 асептикалық некроз эпидемиясына алып келуде. Мақаланың мақсаты әдебиеттерде көрсетілген деректермен өз тәжірибемізде кездескен науқастардағы остеонекроздарды талдау, сонымен қатар, Covid-19 және остеонекроз арасындағы мүмкін болған байланысты, оның ішінде SARS-Cov-2-ні глюкокортикоидтармен емдеуді талқылау. The fourth year of the SARS-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus-2, Covid-19) pandemic is started, which has already claimed more than 6,800,000 lives, is coming to an end. Сlinicians (primarily rheumatologists, traumatologists, general practitioners) are more often facing a new problem – osteonecrosis (aseptic necrosis) of the femoral head, a severe disabling disease. The Covid-19 pandemic has led to an increase in the incidence of aseptic necrosis. We may be on the threshold of an epidemic of osteonecrosis, given the big amount of people who recovered from Covid-19 and were given glucocorticoids as part of SARS-Cov-2 therapy. Over the past 3 years there has been an almost threefold increase of cases in the «Medical Center for Joint Diseases in Shymkent». It is likely that the SARS-Cov-2 pandemic is leading to an epidemic of aseptic necrosis, both due to direct exposure to the virus and because of therapy. The purpose of the article is to analyze literature data and own cases of patients with osteonecrosis and to discuss a possible relationship between osteonecrosis and Covid-19, including the treatment of SARS-Cov-2 with glucocorticoids.

  • Open Access

    Giant Renal Angiomyolipoma by the Example of Clinical Cases

    by S. V. Yadrentseva, N. V. Nudnov, Emil’ G. Gasymov

    The paper presents two clinical cases of patients with giant renal angiomyolipomas (AML), in one of whom its course was complicated by intratumoral hemorrhage. It describes key diagnostic criteria for computed tomography (CT), as well as the distinctive features of other neoplasms that should undergo a differential diagnosis. The similar clinical presentations and morphological characteristics of different renal neoplasms can cause certain diagnostic difficulties; however, the carefully collected historical data and distinctive criteria allow AML to be identified. Due to its high sensitivity and specificity, abdominal contrast-enhanced CT is an effective imaging technique in the detection and differential diagnosis of giant renal AML.


  • Open Access

    CT Diagnosis of Complications Arising from the Natural History and Treatment of COVID-19

    by S. V. Yadrentseva, N. V. Nudnov, E. G. Gasymov, E. V. Pron’kIna

    Computed tomography for coronavirus infection (COVID-19) is effective not only in making a diagnosis, but also in timely and accurately detecting some complications of this disease in different organs and systems. The paper shows various complications of coronavirus infection that a radiologist may face in practice, which develop both in the natural course and due to therapy for COVID-19, including hemorrhagic and thrombotic events in coagulopathy, pneumothorax, and pneumomediastinum as a result of the direct cytotoxic effect of SARS-CoV-2 on pneumocytes, and barotrauma during mechanical ventilation, as well as pathological fractures due to osteoporosis, including steroid osteoporosis that has developed during therapy with glucocorticosteroids. It considers the main causes and pathogenesis of various complications of coronavirus infection.


  • ФИБРОЗНО-МЫШЕЧНАЯ ДИСПЛАЗИЯ ПОЧЕЧНЫХ АРТЕРИЙ (СОВРЕМЕННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ)

    by E.G. Gasymov, R.A. Abdulgasanov

    Фиброзно-мышечная дисплазия является редким, невоспалительным заболеванием сосудов, характеризующимся стенозом неатеросклеротического генеза, поражающим преимущественно детей и женщин молодого возраста. В подавляющем большинстве случаев поражаются почечные артерии, что приводит к вторичной артериальной гипертензии. Большинство неинвазивных скрининговых методов исследования неэффективны в выявлении стеноза почечных артерий, однако ангиография обычно позволяет подтвердить диагноз. Транслюминальная баллонная ангиопластика является терапией выбора, однако при отсроченной терапии данный метод может быть неэффективным в нормализации артериального давления. При возникновении рестеноза требуется дальнейшее наблюдение. Фиброзно-мышечная дисплазия является редким, невоспалительным заболеванием сосудов, характеризующимся стенозом неатеросклеротического генеза, поражающим преимущественно детей и женщин молодого возраста. В подавляющем большинстве случаев поражаются почечные артерии, что приводит к вторичной артериальной гипертензии. Большинство неинвазивных скрининговых методов исследования неэффективны в выявлении стеноза почечных артерий, однако ангиография обычно позволяет подтвердить диагноз. Транслюминальная баллонная ангиопластика является терапией выбора, однако при отсроченной терапии данный метод может быть неэффективным в нормализации артериального давления. При возникновении рестеноза требуется дальнейшее наблюдение.